Spun out in 2007 by Oxford University Innovation, the company has commercialised technological breakthroughs in a new generation of biomarkers for cancer and other diseases.
Its main platform, EpiSwitch, utilises Biodynamics’ biomarker evaluating technology to increase the success rates of drugs pass Phase I clinical trials. The company raised £20m ahead of its flotation, and has been trading steadily around the 160p mark.
For more on Oxford Biodynamics, please visit: http://www.oxfordbiodynamics.com/
For more on the flotation, please visit Proactive Investors or Shares Magazine.